Login to Your Account

Washington Roundup

Vivus Hopes Second Time's a Charm for Qnexa in Obesity

By Mari Serebrov
Washington Editor

Tuesday, February 21, 2012

WASHINGTON – Armed with more information about cardiovascular and teratogenic risks, as well as a less restrictive risk evaluation and mitigation strategy (REMS), Vivus Inc. is prepared for a second performance before the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription